* Axcella Health Inc AXLA.OQ AXLA.O is expected to show no
change in quarterly revenue when it reports results on November
10 (estimated).
* Refinitiv's mean analyst estimate for Axcella Health Inc is
for a loss of 46 cents per share. For the same quarter last
year, the company reported a loss of 34 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Axcella Health
Inc is $11, about 71.4% above its last closing price
of $3.15.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Jun. 30 2021 -0.41 -0.43 -0.42 Beat 1.8
Mar. 31 2021 -0.42 -0.42 -0.40 Beat 4
Dec. 31 2020 -0.32 -0.36 -0.40 Missed -10.8
Sep. 30 2020 -0.39 -0.41 -0.34 Beat 16.6
Jun. -0.53 -0.56 -0.48 Beat 14.6
30 2020
Mar. 31 2020 -0.84 -0.86 -0.65 Beat 24.2
Dec. 31 2019 -0.74 -0.68 Beat 7.7
Sep. 30 2019 -0.65 -0.71 -0.75 Missed -5.6
This summary was machine generated November 8 at 17:51 GMT. All
figures in US dollars unless otherwise stated